- Companies
- Restor3d
Restor3d Valuation, Funding & Investors
Restor3d is valued at $266M as of August 2025.
Last Restor3d valuation
$266M
Series B · Aug 2025
Last Restor3d funding round
$104M
Series B · Aug 2025
Cumulative funding Restor3d raised
$277M
across 10 funding rounds
Key investors in Restor3d
Summers Value Partners
Partners Group
Duke Angel Network
About Restor3d
Restor3d is a Durham, North Carolina-headquartered medical device company specializing in 3D-printed orthopedic implants. The firm produces patient-specific titanium craniomaxillofacial plates, spinal spacers, and pelvic reconstruction devices using AI-optimized designs for osseointegration. FDA-cleared products serve surgeons at hospitals like Mayo Clinic, integrating digital planning software for precise anatomical fits in trauma and oncology cases.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$266M (Aug 2025)
Restor3d Valuation
Restor3d is currently valued at $266M, based on its Series B in August 2025.
The $104M round was led by Partners Group.
Restor3d valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Aug 2025 | Series B | $266M |
Restor3d Funding History
Restor3d has raised a total of $277M across 10 funding rounds.
Restor3d's first fundraising round was a $700K seed round in December 2017. The most recent completed round was a $104M Series B in August 2025.
Restor3d funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Aug 2025 | Series B | Partners Group (lead) | $104M | $266M | Restor3d is a Durham, North Carolina-based medical device manufacturer specializing in AI-driven, 3D-printed personalized orthopedic implants and digital surgical planning tools. The company leverages proprietary expertise in osseointegrative 3D printing materials, AI-based design automation, and digital health solutions to deliver patient-specific joint replacement implants including shoulder, hip, knee, foot, and ankle systems. The company had partnered with over 520 surgeons across 740 U.S. hospitals and received FDA clearance for multiple orthopedic device categories. In August 2025, restor3d announced a strategic investment round in which Partners Group, one of the largest global private markets firms, acquired a significant minority stake for $65 million, with an additional $39 million raised from existing shareholders, totaling $104 million. This marked the company's first institutional investment. Partners Group joined restor3d's board of directors as part of the agreement. The proceeds were earmarked to accelerate product innovation, expand commercial growth, and broaden access to personalized orthopedic care. The company achieved a post-money Series B-1 valuation of $265.79 million as of August 2025. Earlier in 2025, restor3d had completed a $38 million growth round in April from existing and new investors including Summers Value Partners, with proceeds deployed toward commercializing four new fully 3D-printed product lines scheduled for 2025 and 2026 launch. The company reported rapid year-over-year growth and was approaching positive operating cash flow by mid-2025, indicating strong commercial traction in the personalized orthopedic implant market driven by aging demographics and increased sports and recreational participation. |
| Apr 2025 | Undisclosed stage | Summers Value Partners (lead) | $38M | - | Restor3d, a Durham, N.C.-based leader in 3D-printed, personalized orthopedic implants, secured $38 million in growth capital on April 4, 2025, from existing and new private investors including Summers Value Partners. The funding supports commercialization of four new fully 3D-printed product lines in 2025 and 2026, including the Identity3D Porous Cement Total Knee system (FDA-cleared), Kinos Stem Total Ankle System (FDA-cleared), and Velora3D Porous Acetabular System (pending FDA approval). The company leverages AI-driven design, 3D printing of osseointegrative materials, and digital health solutions for patient-specific musculoskeletal implants in shoulder, hip, knee, foot, and ankle procedures. This round brings restor3d's total funding to between $188 million and $210 million, following a $70 million Series A in 2024 ($55 million equity including Summers Value Partners, $15 million debt from Trinity Capital). CEO Kurt Jacobus highlighted the capital's role in scaling technology, expanding personalized care access, and driving year-over-year growth while approaching positive operating cash flow. The company partners with over 520 surgeons across 740 U.S. hospitals and employs around 400 workers. Later in 2025, restor3d raised $104 million, with Partners Group acquiring a significant minority stake for $65 million and existing shareholders adding $39 million, marking its first institutional investment. This supported product innovation, commercial growth, and board expansion. Restor3d operates in a 3D printing market projected to reach $4 billion by 2026 at 21% CAGR. |
| Jun 2024 | Series A | Summers Value Partners (lead) | $55M | - | Restor3d is a leader in 3D-printed, patient-specific orthopedic implants, leveraging proprietary expertise in 3D printing of osseointegrative materials, AI-based planning and design automation, and digital health solutions to optimize musculoskeletal reconstruction outcomes. The company partners with surgeons across hundreds of U.S. hospitals, offering personalized implants for shoulder, hip, knee, foot, and ankle procedures, and recently launched products like the Aeros Modular Stem Total Ankle System. In June 2024, restor3d closed a $70 million financing round consisting of a $55 million Series A equity raise led by private investors including Summers Value Partners, plus existing investors, and $15 million in debt financing led by Trinity Capital. The funds will support investments in advanced 3D printing technologies to expand in-house production capacity, shorten implant delivery times, and reduce costs; enhancements to software and design automation for faster case processing; and expanded educational initiatives for surgeons and sales teams. This round followed other financings, including a $38 million growth capital raise in April 2025 with Summers Value Partners participation, bringing total equity raised toward $188 million, and a prior $104 million round with Partners Group acquiring a significant minority stake for $65 million. Restor3d reported strong year-over-year growth, rapid market share gains, and is approaching positive operating cash flow. The company aims to scale personalized orthopedic solutions amid trends like aging demographics and increased sports participation, redefining standards in orthopedic treatment through improved surgical precision, patient outcomes, and efficiency. |
| Feb 2024 | Undisclosed stage | - | $21M | - | restor3d is a medical device company specializing in AI-driven, 3D-printed personalized orthopedic implants for joints including shoulder, hip, knee, foot, and ankle, partnering with over 520 surgeons across 740 US hospitals. restor3d benefits from trends like aging demographics and sports activities, with recent FDA clearances for products like the iTotal Identity CR knee system. In August 2025, it raised $104 million total, with Partners Group acquiring a significant minority stake for $65 million in new equity and existing shareholders contributing $39 million, to accelerate product innovation, commercial growth, and access to personalized care. Earlier, on April 4, 2025, it secured $38 million in a Series A - II round from Summers Value Partners and others for expansion and launching four new 3D-printed product lines in 2025-2026, approaching positive operating cash flow. The company previously raised $70 million including $55 million Series A and $15 million debt, and in February 2024 a $20.75 million venture round. |
| Sep 2023 | Undisclosed stage | - | $17M | - | Restor3d develops 3D printed patient-specific musculoskeletal implants using proprietary osseointegrative materials, AI-based planning, and digital health solutions to optimize patient outcomes in orthopedic care. In 2024, the company closed a $70 million financing round comprising a $55 million Series A led by Summers Value Partners and existing investors, plus $15 million in debt from Trinity Capital. The funds support launch of new implant systems for ankle and shoulder replacements, advancements in hip and knee portfolios, investments in advanced additive manufacturing processes, software, AI automation, and expanded medical education programs. |
| Mar 2022 | Undisclosed stage | - | $23M | - | Restor3d is a Durham, North Carolina-based company specializing in 3D printed, patient-specific musculoskeletal implants using proprietary osseointegrative materials, AI-based planning, design automation, and digital health solutions to optimize orthopedic outcomes. The company emphasizes personalized orthopedic care, surgical precision, and efficiency, reimagining musculoskeletal reconstruction. The funding enabled commercialization of products such as the Veritas Reverse Total Shoulder System, Modular Stem Total Ankle System, and Velora 3DP Porous Acetabular System, featuring TIDAL Technology for bone integration. This preceded larger financings, including a $55M Series A plus $15M debt (totaling $70M) led by Summers Value Partners and Trinity Capital, announced around mid-2024, to support new implant systems like femoral implants, advanced additive manufacturing, software/AI automation, and medical education programs. Subsequent raises included $38M in growth capital in April 2025 from private investors including Summers Value Partners for four new 3D printed product lines in 2025-2026 and market expansion, with the company reporting strong year-over-year growth and approaching positive operating cash flow. In August 2025, restor3d secured $104M in a growth round where Partners Group took a significant minority stake with $65M, alongside $39M from existing shareholders, to fuel product innovation and commercial scaling. |
| May 2021 | Series A | - | $13M | - | - |
| Jan 2020 | Series A | - | $5M | - | - |
| May 2018 | Seed | Duke Angel Network | $400K | - | - |
| Dec 2017 | Seed | - | $700K | - | - |
Who has invested in Restor3d?
3 investors have backed Restor3d across its funding rounds, including Summers Value Partners, Partners Group and Duke Angel Network.
Lead investors include Partners Group and Summers Value Partners.
Restor3d Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Jun 2024 | ||
This data is available for Pro users. Sign up to see all 3 Restor3d investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Restor3d
Restor3d has acquired 2 companies to date.
Last acquisition by Restor3d was on June 22nd 2023. Restor3d acquired ConforMIS for $18M.
Latest Acquisitions by Restor3d
| Description | ConforMIS is a Billerica-headquartered medical device company producing personalized knee and hip replacement implants via its iFit Image-to-Implant technology. The platform converts patient CT scans into custom-fitted implants and single-use instruments for total and partial knee systems like iTotal and iUni, plus hip systems such as iHip. Delivered sterile to hospitals and surgery centers across the United States, Europe, and Asia. | Kinos Medical is a developer of orthopedic implants for ankle arthritis preservation. Its Kinos Inlay device replaces arthritic joint surfaces while maintaining natural motion during total ankle arthroplasty. Cleared by the FDA in 2022, the implant integrates with systems from DePuy Synthes and Zimmer Biomet, used in surgeries across North American hospitals to improve patient outcomes. |
| HQ Country | ||
| HQ City | - | Philadelphia, PA |
| Deal Date | 22 Jun 2023 | 15 May 2021 |
| Valuation | $18M | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Restor3d acquisitions and their M&A valuation multiples. Start Free Trial | ||
Restor3d Competitors
Restor3d competitors include listed companies like Graphy and Infinitt Healthcare, and private ones like AMT, Lightforce Orthodontics, Kwivik Therapeutics Inc and Koniku.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $218M | - | ||
| Private | - | - | $400M | - | ||
| Publicly listed | $15M | ($7M) | $136M | 6.5x | ||
| Private | - | - | $213M | - | ||
| Private | - | - | $337M | - | ||
| Publicly listed | $75M | $27M | $238M | - |
Restor3d Public Comps
Restor3d is still privately-owned, but its public comps include Surgical Science, Tess Holdings Co, NN, Medipost, Dong-A ST, Anika Therapeutics, InfuSystem, Standard BioTools, Anbio Biotechnology and OraSure.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $101M | $18M | 1.9x | 1.9x | 11.2x | 9.4x | |||
| $236M | $37M | 3.1x | 2.2x | 19.8x | - | |||
| $422M | $17M | 1.4x | 1.3x | 34.5x | 10.5x | |||
| $54M | ($59M) | 4.3x | 4.7x | (3.9x) | (9.7x) | |||
| $589M | $6M | 0.8x | 0.8x | 84.0x | 10.1x | |||
| $113M | ($5M) | 2.4x | 2.2x | (50.4x) | 17.9x | |||
| $143M | $25M | 1.9x | 1.9x | 10.7x | 8.5x | |||
| $85M | ($95M) | - | - | - | - | |||
This data is available for Pro users. Sign up to see all Restor3d competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Restor3d
| When was Restor3d founded? | Restor3d was founded in 2017. |
| Where is Restor3d headquartered? | Restor3d is headquartered in Durham, NC, United States. |
| Is Restor3d publicly listed? | No, Restor3d is a private, VC-backed company. |
| What is Restor3d's valuation? | Restor3d was last valued at $266M in its Series B in August 2025. |
| How much funding has Restor3d raised? | Restor3d has raised $277M across 10 funding rounds. |
| What was Restor3d's last funding round? | Restor3d's last funding round was a $104M Series B in August 2025, led by Partners Group. |
| Who are Restor3d's investors? | Restor3d's investors include Summers Value Partners, Partners Group and Duke Angel Network. |
| Which companies are comparable to Restor3d? | Companies comparable to Restor3d include AMT, Lightforce Orthodontics, Graphy, Kwivik Therapeutics Inc, Koniku and Infinitt Healthcare. |
| How many companies has Restor3d acquired? | Restor3d has acquired 2 companies, including ConforMIS and Kinos Medical. |
| What was the largest acquisition by Restor3d? | The $18M acquisition of ConforMIS in June 2023 is the largest acquisition Restor3d has made to date. |
See companies similar to Restor3d
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




